Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.

Anna C FerrariJoshi J AlumkalMark N SteinMary-Ellen TaplinJames BabbEthan S BarnettAlejandro Gomez-PinillosXiaomei LiuDirk F MooreRobert DiPaolaTomasz M Beer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

The 40 mg panobinostat/bicalutamide regimen increased rPF survival in CRPC patients resistant to 2ndLAARx. Panobinostat toxicity was tolerable with dose reductions. Epigenetic HDACI therapy reduces AR-mediated resistance to bicalutamide in CRPC models with clinical benefit in patients. The combination merits validation using a second-generation antiandrogen.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
dna methylation
gene expression
prognostic factors
stem cells
patient reported outcomes
smoking cessation